QVHLSET
QuicTPD™ VHL ligand set
packaging
pkg of 50 mg
Quality Level
sustainability
Greener Alternative Product
greener alternative category
storage temp.
2-8°C
Related Categories
General description
(S,R,S)-AHPC and (S,R,S)-AHPC-Me are recruiters of von-Hippel-Lindau (VHL) protein that can be leveraged for targeted protein degradation research. They are provided at 50 mg each.
We are committed to bringing you Greener Alternative Products. This product is a Design for Sustainability (DfS) developed product, which belongs to one of the four categories of greener alternatives. Click here to view its DfS scorecard.
Application
Useful for construction of VHL based partial protacs of full protacs, by utilizing the amine terminus to add suitable linkers with peptide coupling reactions. These can also be used as controls/competitors to confirm target engagement of putative protacs.
Features and Benefits
Quantities provided are sufficient to do atleast 96 reactions at 1 micromole each with a D2B approach with a library of suitable bifunctional linkers ending in carboxylic acid terminus to generate a library of partial protacs or full protacs.
Other Notes
VHL Ligand Set part of QuicTPD™ kit
Legal Information
QuicTPD is a trademark of Merck KGaA, Darmstadt, Germany
Kit Components Also Available Separately
Product No.
Description
SDS
- 901526Pomalidomide-PEG2-CO2H, 95%SDS
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Xin Han et al.
Journal of medicinal chemistry, 62(2), 941-964 (2019-01-11)
We report herein the discovery of highly potent PROTAC degraders of androgen receptor (AR), as exemplified by compound 34 (ARD-69). ARD-69 induces degradation of AR protein in AR-positive prostate cancer cell lines in a dose- and time-dependent manner. ARD-69 achieves
Ashton C Lai et al.
Angewandte Chemie (International ed. in English), 55(2), 807-810 (2015-11-26)
Proteolysis Targeting Chimera (PROTAC) technology is a rapidly emerging alternative therapeutic strategy with the potential to address many of the challenges currently faced in modern drug development programs. PROTAC technology employs small molecules that recruit target proteins for ubiquitination and
Articles
Discover QuicTPD™ Acid/Amine Screening Sets for rapid, high-throughput PROTAC® synthesis, streamlining targeted protein degradation research.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service